AOD-9604
Tier 3 · Reported useAOD-9604 completed six randomized double-blind placebo-controlled human trials (2001-2006, ~890-900 participants), supporting a Tier 1 designation for the obesity/safety data. However, human efficacy for weight loss was not established—the pivotal 24-week Phase IIb trial failed its primary endpoint and 12-week signals did not reach significance (P=0.07). Much of the mechanistic and dosing detail derives from lower-tier vendor/marketing sources, while joint/cartilage claims rest on animal (rabbit) models. Sources disagree on IGF-1 effects and half-life values.
- Half-life
- ~0.5 h
- Routes
- Oral (capsules/tablets — used in human trials) · Intravenous (human PK trials) · Subcutaneous (animal and community/off-label use) · Intraperitoneal (animal studies) · Intra-articular (animal osteoarthritis model) · Topical (licensed anti-cellulite formulation)
- Goals
- fat loss · body composition · healing
- Cost / mg
- Not recorded
How it works
AOD-9604 is a small synthetic peptide copied from the tail end (C-terminal fragment) of human growth hormone—the portion thought to be responsible for growth hormone's fat-burning activity, separate from its growth-promoting and blood-sugar effects. It was designed to encourage the body to break down fat (lipolysis) and reduce the formation of new fat (lipogenesis) without raising blood glucose, suppressing the pituitary axis, or elevating IGF-1. Unlike full growth hormone, it does not meaningfully bind the classical growth hormone receptor or cause cell proliferation. Its fat effects appear linked to activity involving the beta-3 adrenergic receptor pathway in fat cells, though animal knockout studies suggest the effect is not directly mediated through that receptor.
Overview
Overview
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (variously described as residues 176-191 or 177-191), with an added N-terminal tyrosine substituted for stability and oral bioavailability. Its reported sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF), and two cysteine residues (positions 7 and 14) form an intramolecular disulfide bond creating a constrained cyclic region whose 3D structure resembles the homologous region of complete hGH. Molecular weight is approximately 1,815-1,817 Da (C78H123N23O23S2, CAS 221231-10-3).
Design Rationale
The C-terminal region of hGH (residues 177-191) contains the structural elements responsible for the lipolytic (fat-mobilizing) activity of growth hormone, independent of its growth-promoting or diabetogenic effects. AOD-9604 was designed to stimulate lipolysis and inhibit lipogenesis without raising blood glucose, suppressing the hypothalamic-pituitary axis, or elevating IGF-1. Notably, one source dissents from this consensus, characterizing AOD-9604 as a growth hormone secretagogue that activates IGF-1 signaling and satellite cell repair; the large majority of sources contradict this.
Development History
AOD-9604 was originally developed in the 1990s by researchers at Monash University in Australia (attributed to Professor Frank Ng) through the spin-out Metabolic Pharmaceuticals as a potential anti-obesity treatment. Between 2001 and 2006 it advanced through six randomized double-blind placebo-controlled human clinical trials involving roughly 890-900 participants (predominantly obese adults, with one trial including healthy non-obese volunteers). The portfolio comprised three single-dose pharmacokinetic studies and three multiple-dose efficacy trials, two extending up to 24 weeks. Phase IIa trials were underway by February 2002.
Clinical Efficacy for Weight Loss
In a 12-week trial (METAOD005), participants receiving 1 mg/day oral AOD-9604 lost approximately 2.6 kg versus 0.8 kg on placebo (one source reports ~2.76 kg vs ~0.84 kg), a difference that did not reach statistical significance across the pooled program (P=0.07). An earlier 12-week trial showed a modest positive signal with 1 mg/day producing approximately 1.8 kg more weight loss than placebo. However, the pivotal 24-week Phase IIb trial (OPTIONS / METAOD006), enrolling 536 obese adults (one source says ~300), failed to demonstrate statistically significant weight loss versus placebo, leading Metabolic Pharmaceuticals to discontinue obesity development in early 2007. Human efficacy for weight loss was therefore not established.
Animal Evidence
Animal studies were more encouraging: AOD-9604 induced weight loss and increased lipolytic sensitivity following long-term treatment in mice, reduced body weight and fat in obese mice after 14 days of chronic IP administration, increased in vivo fat oxidation and plasma glycerol, and produced effects comparable to full-length hGH but without insulin-disrupting side effects. Injected AOD-9604 produced roughly 50% greater reduction in body fat mass versus saline over 7 weeks in mice, and daily oral dosing at 500 μg/kg for 19 days reduced body-weight gain over 50% in obese Zucker rats.
Post-Obesity Applications
After obesity development ended, AOD-9604 was investigated for osteoarthritis, cartilage repair, and joint recovery. In a collagenase-induced knee osteoarthritis rabbit model, intra-articular AOD-9604 enhanced cartilage regeneration, and AOD-9604 combined with hyaluronic acid was more effective than either alone. It was subsequently licensed to Phosphagenics for a topical anti-cellulite formulation and to other parties for nutraceutical, osteoarthritis, and cosmetic uses—none of which produced an approved therapeutic. These rebranded joint-health uses rest on animal models and have almost no published human evidence.
Pharmacokinetics
AOD-9604 demonstrates approximately 40% oral bioavailability in animal models; in pigs it was well absorbed with rapid degradation kinetics, and rat whole-body radiography revealed similar organ distribution after IV or oral application. Six potential serum/urine metabolites were identified, with one (CRSVEGSCG) notably more stable than the parent or other metabolites. A validated urine solid-phase extraction detection method achieved a 50 pg/mL limit of detection.
What the research shows
71 findings extracted from the 17 sources cited below, strongest evidence first within each group. Every one links to the source it came from.
What human studies found
Based on 15 animal findings and 1 expert opinion finding.
animalAOD9604 is capable of inducing weight loss following long-term treatment in mice2
animalAOD9604 can reduce body weight and body fat in obese mice following 14 d of chronic ip administration2
animalAOD9604 is capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice2
animalAOD9604 can reduce body weight and body fat in obese mice following 14 d of chronic ip administration2
animalAOD9604 intra-articular injections enhanced cartilage regeneration in collagenase-induced knee osteoarthritis rabbit model4
animalCombined AOD9604 and HA injections were more effective than HA or AOD9604 injections alone in collagenase-induced knee OA rabbit model4
animalMean gross morphological and histopathological scores were significantly higher in saline control group than in AOD9604, HA, and combined treatment groups4
animalCombined AOD9604 and HA group had significantly lower morphological and histopathological scores than HA or AOD9604 alone4
Show 8 more findingsShow fewer
animalLameness period in combined AOD9604 and HA group was significantly shorter than in saline, HA, and AOD9604 alone groups4
animalLameness period in saline control group was significantly longer than in HA and AOD9604 groups4
animalEarly stage studies with AOD9604 have shown positive activities on fat metabolism5
animalSystemic hGH treatment in rodents and humans influences fat distribution, particularly abdominal fat, and reduces body fat mass5
animalBoth hGH and AOD9604 significantly reduced body weight gain in obese mice7
animalDaily oral treatment with AOD9604 at 500 microg/kg body weight for 19 days reduced body weight gain over 50% in obese Zucker rats compared to control8
animalMany unapproved peptides including AOD-9604 demonstrate favorable tissue repair and metabolic outcomes in animal models9
expert opinionBy February 2002, phase IIa trials were underway16
How it works
Based on 18 animal findings, 2 in vitro findings, 4 expert opinion findings and 6 theoretical findings.
animalAOD9604 is a lipolytic fragment synthesized from the C-terminus of human GH2
animalAOD9604 increases lipolytic sensitivity following long-term treatment in mice2
animalAOD9604 increases the level of expression of beta(3)-AR RNA in obese mice2
animalAOD9604 increases repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice2
animalLong-term treatment with AOD9604 in beta(3)-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice2
animalIn acute experiments, AOD9604 was capable of increasing energy expenditure and fat oxidation in beta(3)-AR knock-out mice2
animalThe lipolytic actions of AOD9604 are not mediated directly through the beta(3)-AR although AOD9604 increases beta(3)-AR expression2
animalAOD9604 is a lipolytic fragment synthesized from the C-terminus of human GH2
Show 22 more findingsShow fewer
animalAOD9604 treatment correlates with increases in the level of expression of beta(3)-AR RNA, the major lipolytic receptor found in fat cells2
animalAOD9604 is capable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice2
animalLong-term treatment with AOD9604 in beta(3)-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice2
animalIn an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in beta(3)-AR knock-out mice2
animalThe lipolytic actions of AOD9604 are not mediated directly through the beta(3)-AR although AOD9604 increases beta(3)-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity2
animalAOD9604 treatment was associated with increased in vivo fat oxidation in obese mice7
animalAOD9604 treatment increased plasma glycerol levels (an index of lipolysis) in obese mice7
animalAOD9604 acts in a manner novel to traditional hGH-stimulated pathways7
animalAOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone (hGH)8
animalAdipose tissues of AOD9604-treated animals showed increased lipolytic activity8
in vitroAOD9604 does not compete for the hGH receptor7
in vitroAOD9604 does not induce cell proliferation, unlike hGH7
expert opinionAOD-9604 is a growth hormone secretagogue that activates IGF-1 signaling and satellite cell repair10
expert opinionAOD9604 affects biological mechanisms that suppress appetite and absorb nutrients to regulate body weight12
expert opinionAOD-9604 is a human growth hormone fragment that increases adipose tissue breakdown14
expert opinionAOD9604 is a drug that improves adipose tissue function or fatty acid metabolism15
theoreticalAOD9604 is a peptide consisting of the C-terminal fragment of human growth hormone from amino acids 177-191 with an additional tyrosine residue at the N-terminus3
theoreticalAOD9604 mimics the lipolytic properties of growth hormone without the diabetogenic side effects3
theoreticalAOD9604 is the C-terminal fragment (Tyr-hGH177-191) of human growth hormone (hGH)5
theoreticalAOD9604 is prepared by solid phase peptide synthesis and contains an additional tyrosine at the N-terminal end for peptide stabilization and is cyclized by disulphide bonding between the two cysteine residues5
theoreticalThe 3D structure of AOD9604 is similar to the homologous region of complete hGH5
theoreticalIn adipose tissue hGH can induce inhibition of lipoprotein lipase activity, thus stimulating lipolysis and resulting in a reduction of fat cell mass5
How the body handles it
Based on 2 animal findings and 2 in vitro findings.
animalRat whole-body radiography revealed similar organ distribution after IV or oral application5
animalOrally administered AOD9604 in pigs was well absorbed and results revealed rapid degradation kinetics5
in vitroSix potential metabolites of the peptide were identified after incubation of AOD9604 in serum and urine3
in vitroA single metabolite consisting of amino acids CRSVEGSCG was identified in serum that is significantly more stable than other metabolites or the parent compound3
Safety and side effects
Based on 1 human study finding, 5 animal findings and 1 expert opinion finding.
human studyAOD9604 has been evaluated for safety and tolerability in humans1
animalAOD9604 was found to be generally safe after chronic oral application in rats and cynomolgus monkeys5
animalThere was no evidence of any genotoxic activities of AOD9604, as examined in an Ames test, a chromosomal aberration assay, or a bone micronucleus assay5
animalMultiple non-clinical studies revealed no evidence of genotoxicological or toxicological concerns regarding the safety of AOD96045
animalUnlike hGH, AOD9604 did not induce hyperglycaemia or reduce insulin secretion7
animalChronic treatment with AOD9604 showed no adverse effect on insulin sensitivity in animals, as demonstrated with euglycemic clamp techniques8
expert opinionRigorous human safety data for unapproved peptides like AOD-9604 are scarce9
What people use it for
Based on 1 animal finding, 9 expert opinion findings and 1 theoretical finding.
animalAOD9604 has potential to be developed into an orally usable and safe therapeutic agent for obesity8
expert opinionAOD9604 is banned by the World Anti-doping Agency (WADA)3
expert opinionAOD-9604 is an anti-obesity drug9
expert opinionAOD-9604 is among prominent unapproved peptides marketed direct to patients9
expert opinionAOD-9604 is classified as a doping agent according to World Anti-Doping Agency regulations11
expert opinionAOD-9604 is a peptidic substance of potential performance-enhancing nature11
expert opinionAOD9604 is a recent patented anti-obesity drug that can reduce adiposity at the molecular level12
expert opinionAOD9604 is a human growth hormone fragment under clinical development as an antiobesity agent13
Other findings
Based on 1 human study finding and 2 in vitro findings.
Points of contention
Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.
Contested
Reported half-life varies across sources, and human pharmacokinetics remain poorly characterized.
Published half-life figures differ, partly because they describe different routes and measurements: about 30 minutes after subcutaneous injection (AOD 9604: What the Research Actually Shows About This HGH Fragment; AOD-9604 (Fragment 176-191): 2026 Dosing & Status), about 3 minutes intravenously (AOD-9604: HGH Fragment Research Overview), and about 4 minutes as a serum half-life (AOD-9604 Metabolic Support Process: Complete Mechanism Guide). None of these represent a settled value: AOD-9604 (Anti-Obesity Drug 9604): Research Evidence & Safety Profile states the half-life is not well characterized in humans and that the peptide is rapidly degraded in serum, consistent with the rapid degradation kinetics reported in Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient.
Limited evidence
Human efficacy for weight loss was not established; the key trial failed its endpoint.
While 12-week trials showed a modest weight-loss signal (~2.6 kg vs 0.8 kg placebo), this did not reach statistical significance (P=0.07), and the pivotal 24-week Phase IIb trial failed to show significant weight loss versus placebo, ending obesity development in 2007.
Limited evidence
Joint/cartilage and other rebranded uses have little to no human evidence.
Cartilage-repair and osteoarthritis claims rest on animal (rabbit) models and expert opinion; AOD-9604: HGH Fragment Research Overview | Peptidings explicitly notes rebranding as a joint-health supplement is a different claim with almost no published evidence, and AOD-9604 (Fragment 176-191): 2026 Dosing & Status notes none of the post-obesity applications produced an approved therapeutic.
Limited evidence
Much of the mechanistic and dosing detail comes from low-tier vendor/marketing web sources.
Many detailed claims (mechanism, half-life, dosing, GRAS interpretation) are drawn from tier-3 commercial peptide-vendor pages (AOD-9604 (Anti-Obesity Drug 9604): Research Evidence & Safety Profile | PeptideInsight through AOD 9604 Peptide for Fat Loss: Does It Work? | Perfect B) rather than peer-reviewed studies; higher-tier sources (Safety and Metabolism of AOD9604, a Novel Nutraceutical ..., Safety and Tolerability of the Hexadecapeptide AOD9604 ..., AOD-9604 Safety Profile: What Clinical Trials Show - Beverly Hills Rejuvenation Center, The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice - PubMed, Detection and in vitro metabolism of AOD9604., Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model., Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment., Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.) are largely animal, in vitro, or safety/tolerability studies.
Inconsistency
The broad "excellent safety" reassurance comes from a clinic's promotional blog, not from the trial reports themselves.
The sweeping conclusion that AOD-9604 has "demonstrated excellent safety and tolerability" is drawn from a commercial marketing page published by the Beverly Hills Rejuvenation Center, which advertises its own "Regenerative Aesthetic Services" and peptide-related treatments. The page summarizes trials run between 2001 and 2006 involving roughly 900 participants across six randomized, double-blind, placebo-controlled studies, but as a promotional secondary source it restates these figures rather than presenting the underlying safety data, and it has a commercial interest in a favorable conclusion.
What you may have heard
AOD-9604's strongest human evidence concerns safety and tolerability, not weight loss — the pivotal weight-loss trial failed and efficacy was never established.
Readers will often see AOD-9604 described as unusually well-supported for a research peptide, backed by six controlled human trials in roughly 900 participants. That impression rests on safety and tolerability work — such as the published human safety/tolerability study and a clinic marketing page emphasizing an 'excellent safety profile' — not on demonstrated weight loss. The pivotal 24-week Phase IIb trial (OPTIONS/METAOD006, 536 obese adults) failed its primary endpoint, and the shorter 12-week weight-loss signals did not reach statistical significance across the program (P=0.07). In other words, the trials established that the peptide was well tolerated, not that it produces meaningful weight loss.
What you may have heard
The beta3-AR–dependent lipolysis via cAMP elevation and hormone-sensitive lipase activation is presented as the operativ…
Claim 8 (beta3-AR-dependent cAMP/HSL pathway) is grounded almost entirely in tier-3 vendor pages, while the actual tier-2 knockout study (The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice - PubMed/The effects of human GH and its lipolytic fragment ...) shows the body-weight and lipolytic effects are lost in beta3-AR knockouts yet acute energy expenditure persists — i.e., not directly beta3-AR mediated. The technical section acknowledges this, but stating the cAMP/HSL beta3-AR pathway as the mechanism risks overstating a vendor-derived model the primary literature does not support.
What you may have heard
The clean safety record — no serious adverse events, no immune reactions, no blood-sugar disruption across six trials — is stated only in clinic and vendor write-ups, not in any primary trial report.
The blanket negative safety findings for AOD-9604 (no serious adverse events, no immunogenic responses, no changes in IGF-1, and no glucose or insulin disruption across roughly 900 participants in six trials) are asserted in secondary commercial summaries rather than in the underlying trial publications. The most sweeping version appears in the Perfect B review ('AOD 9604 Peptide for Fat Loss: Does It Work?'), which states all four negatives, and in the Beverly Hills Rejuvenation Center article ('AOD-9604 Safety Profile: What Clinical Trials Show'), which describes 'excellent safety and tolerability' and references immunogenicity data. The HealthRX.com and Kalios summaries restate only the metabolic subset — no rise in fasting insulin, HbA1c, or IGF-1 — and HealthRX adds that there is no long-term human safety data beyond 12 weeks in any published trial. None of these reproduces or points to the primary trial data itself, so the high certainty of a blanket 'no adverse events' claim rests on secondary write-ups rather than published trial reporting.
What you may have heard
A 40% oral bioavailability figure for this 16-amino-acid peptide comes only from a commercial source and sits uneasily with descriptions of rapid serum degradation.
The claim that AOD-9604 shows roughly 40% oral bioavailability in animal models, alongside a serum half-life of about 4 minutes, appears only in a clinic marketing overview (AOD-9604 Metabolic Support Process: Complete Mechanism Guide) and is not accompanied by any primary data. The peer-reviewed pharmacokinetic work in Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient reports only that orally administered AOD9604 in pigs was 'well absorbed' with 'rapid degradation kinetics,' and gives no bioavailability percentage. A 40% figure is unusually high for a peptide that degrades rapidly, and the available material does not establish whether it refers to true systemic bioavailability or merely absorption in a specific animal model, nor whether it reflects intact peptide or metabolites.
Other
The once-daily subcutaneous dosing seen in community use sits awkwardly against a subcutaneous half-life of only about 30 minutes.
The subcutaneous half-life is reported at approximately 30 minutes, so a once-daily injection would leave the peptide largely cleared for most of each day. The gap matters because the injectable route was never the basis of the clinical program: the six completed trials used oral dosing, and the subcutaneous, once-daily protocols circulating in community use are extrapolations from those oral studies and from rodent work rather than regimens that were themselves tested and shown to be effective.
Contested
The apparent weight loss in the 12-week trial was not statistically significant, and the larger, longer trial failed outright.
In the 12-week METAOD005 trial the 1 mg/day oral arm lost roughly 2.6–2.76 kg versus about 0.8–0.84 kg on placebo, but this difference did not reach statistical significance across the pooled program, with a reported P-value of 0.07 against the conventional P<0.05 threshold (per 'AOD 9604: What the Research Actually Shows About This HGH Fragment'). The subsequent, larger 24-week Phase IIb OPTIONS study (n=536) then failed to demonstrate statistically significant weight loss, leading Metabolic Pharmaceuticals to halt the obesity program in 2007 (per 'AOD-9604: Six RCTs, One Failed Phase 2b'). Consistent with this, 'AOD‑9604 Peptide for Fat Loss: Mechanism, Benefits & Risks Explained' states that in the clinical trial AOD-9604 did not demonstrate statistically significant weight loss compared to placebo.
Contested
The sources disagree on whether the 12-week weight-loss result was statistically significant.
Perfect B (AOD 9604 Peptide for Fat Loss: Does It Work?) states the METAOD005 12-week finding (~2.6 kg vs ~0.8 kg placebo) 'was statistically significant.' HealthRX (AOD 9604: What the Research Actually Shows About This HGH Fragment) reports the same 1 mg arm result (~2.76 kg vs ~0.84 kg placebo) but says the difference did not reach statistical significance across the pooled program, citing a P-value of 0.07 (short of the conventional P<0.05 threshold). Kalios (AOD-9604: Six RCTs, One Failed Phase 2b) frames the 12-week result as 'real' while emphasizing that the separate 24-week Phase 2b OPTIONS trial (n=536) failed to demonstrate significant weight loss, after which the developer shelved the obesity program in 2007.
Limited evidence
The confident "excellent safety" summary for AOD-9604 is carried most prominently by a commercial clinic's marketing page.
The sweeping safety narrative for AOD-9604 — excellent safety and tolerability across six randomized, double-blind, placebo-controlled trials involving over 900 participants between 2001 and 2006 — is presented most prominently on a commercial rejuvenation clinic's blog, "AOD-9604 Safety Profile: What Clinical Trials Show." A peer-reviewed human safety publication does exist, "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans," but its detailed findings are not accessible in the material at hand to independently confirm the specific reassurances circulating online.
Using it with other compounds
Proposed as compatible, but the two compounds' own mechanism data did not support the pairing.
- CJC-1295Complementary
May be complementary
CJC-1295 boosts GH (and downstream IGF-1) through the GHRH receptor, a hormone-mediated path to fat mobilization, while AOD-9604 stimulates lipolysis directly at the adipocyte. The two hit fat loss from different directions and are not redundant with each other.
Tier 3Largely anecdotal — commonly discussedShares cAMP PKA
- TirzepatideComplementary
May be complementary
Tirzepatide lowers body weight and fat mass through dual incretin (GIP/GLP-1) appetite and metabolic effects, whereas AOD-9604 directly stimulates fat-cell lipolysis. The two operate by distinct mechanisms converging on fat reduction.
Tier 3Largely anecdotal — commonly discussedShares cAMP PKA
- IpamorelinComplementary
May be complementary
AOD-9604 drives fat mobilization through a GH-independent route (beta-3 adrenergic/HSL activation, not the GH receptor), while ipamorelin promotes lipolysis indirectly via GH release. Because they hit fat metabolism from different directions and both ultimately raise cAMP-driven hormone-sensitive lipase activity, they can be used together for fat-loss goals without receptor competition.
Tier 4Theoretical — not establishedTiming Both are often used fasted; no strict separation required.
Shares lipolysis · cAMP PKA
- TesamorelinComplementary
May be complementary
Both push fat loss but by different routes: tesamorelin raises endogenous growth hormone via the GHRH receptor, while AOD-9604 stimulates fat breakdown directly in fat cells (cAMP rise, hormone-sensitive lipase) without acting on the GH receptor. Because their entry points differ, they can reinforce each other on the same goal of reducing (especially visceral) fat.
Tier 3Largely anecdotal — commonly discussedTiming No strict separation needed; both are commonly dosed on an empty stomach/subcutaneously.
Shares lipolysis · cAMP PKA
- SermorelinComplementary
May be complementary
Sermorelin drives fat loss indirectly by prompting the pituitary to release more of the body's own growth hormone, whereas AOD-9604 acts directly on fat cells to trigger lipolysis. Different upstream triggers converging on the same fat-burning outcome make them potentially additive rather than redundant.
Tier 3Largely anecdotal — commonly discussedShares lipolysis · cAMP PKA
- SemaglutideComplementary
May be complementary
Semaglutide reduces body fat mainly by curbing appetite and improving glucose/insulin handling through the GLP-1 receptor, while AOD-9604 works peripherally to mobilize and oxidize stored fat. Different mechanisms aimed at the same weight/fat-loss goal, so they can complement each other.
Tier 3Largely anecdotal — commonly discussedShares lipolysis
- MOTS-cComplementary
May be complementary
MOTS-c improves fat metabolism and drives fat oxidation/adipose browning via AMPK and mitochondrial signaling, while AOD-9604 mobilizes fat by raising cAMP and activating hormone-sensitive lipase. Mobilization (AOD) plus enhanced oxidation (MOTS-c) are logically complementary steps of the same fat-loss process.
Tier 4Theoretical — not establishedShares lipolysis
- MK-677Stack with caution
Worth caution
MK-677 raises GH/IGF-1 (which can support lipolysis) but also markedly stimulates appetite and can promote fluid retention, potentially working against AOD-9604's fat-loss goal. Worth understanding the appetite trade-off before combining.
Tier 4Theoretical — not established - RetatrutideComplementary
No documented conflict
AOD-9604 mobilizes fat by upregulating beta-3 adrenergic/hormone-sensitive-lipase driven lipolysis and inhibiting lipogenesis, a distinct mechanism from retatrutide's incretin/glucagon-driven appetite and energy-expenditure effects. Both converge on reduced fat mass, so they are complementary for a fat-loss goal, though evidence for the combination specifically is anecdotal.
Tier 4Theoretical — not establishedShares lipolysis
Safety and side effects
Safety Profile
Across all Phase II arms, AOD-9604 did not raise fasting insulin, HbA1c, or IGF-1 compared to placebo. Across the six trials there were no serious adverse events, no immunogenic responses, and no glucose or insulin disruption, and it was reported as well tolerated regardless of delivery route.
Preclinical Safety
AOD-9604 was generally safe after chronic oral application in rats and cynomolgus monkeys, with no evidence of genotoxic activity (Ames test, chromosomal aberration assay, bone micronucleus assay) and no toxicological concerns across multiple non-clinical studies. Unlike hGH, it did not induce hyperglycaemia or reduce insulin secretion in obese mice, and chronic treatment showed no adverse effect on insulin sensitivity as measured by euglycemic clamp.
Regulatory and Legal Status
- AOD-9604 received a self-affirmed GRAS (Generally Recognized as Safe) determination as a food ingredient (self-affirmed 2014), but it is not FDA-approved for any indication and has no approved injectable indication. One source notes a PCAC rejection in December 2024.
- It is not a legally compoundable drug substance in the United States and is among prominent unapproved peptides marketed direct to patients.
- It is banned by the World Anti-Doping Agency (WADA) and classified as a doping agent of potential performance-enhancing nature.
Key Limitations
- No long-term human safety data exist beyond 12 weeks in published trials (though 24-week study periods were conducted), and rigorous human safety data for unapproved peptides like AOD-9604 are described as scarce.
- Much of the mechanistic, dosing, and safety-interpretation detail comes from lower-tier vendor/marketing web sources rather than peer-reviewed studies.
Reconstitution and handling
Administration Routes
No dose has been established for this compound. No regulatory label exists for it, so the figures below are what sources report — not guidance.
Human clinical trials tested intravenous injection and oral formulations (capsules or tablets), with bioavailability differing between routes. Additional routes appearing in the broader literature include subcutaneous (animal and community/off-label use), intraperitoneal (animal studies), intra-articular (animal osteoarthritis model), and topical (the licensed anti-cellulite formulation).
Dosing (as reported)
- Oral doses in human trials, as reported in the published Phase I–II clinical trial literature, ranged from 1 mg to 30 mg per day, with the 1 mg/day arm being the focus of the weight-loss signal.
- Community/off-label research doses are reported around 250-500 mcg subcutaneous (typically once daily), with 300 mcg cited as a typical research dose. These figures derive from low-tier community/vendor sources, not clinical trials.
Storage
AOD-9604 is described as available for research purposes and in select wellness clinics, and is recommended to be stored at 2-8°C.
Note: AOD-9604 is not FDA-approved and is not a legally compoundable substance in the U.S. This section restates reported preparation and dosing information and is not guidance to use the compound.
Sources
Ordered by evidence quality — the strongest first.
- Safety and Tolerability of the Hexadecapeptide AOD9604 ...(opens in a new tab)Tier 1Web · jofem.org · 2013
- The effects of human GH and its lipolytic fragment ...(opens in a new tab)Tier 2Web · pubmed.ncbi.nlm.nih.gov
- Detection and in vitro metabolism of AOD9604.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2015
- Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2015
- Safety and Metabolism of AOD9604, a Novel Nutraceutical ...(opens in a new tab)Tier 2Web · jofem.org · 2014
- AOD-9604 does not influence the WADA hGH isoform immunoassay.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2013
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2001
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2000
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.(opens in a new tab)Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
- Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.(opens in a new tab)Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2014
- Current updates in the medical management of obesity.(opens in a new tab)Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2012
- [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].(opens in a new tab)Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2007
- Obesity drugs in clinical development.(opens in a new tab)Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2006
- Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.(opens in a new tab)Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2006
- AOD-9604 Metabolic.(opens in a new tab)Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2004
- Gateways to clinical trials.(opens in a new tab)Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2003
See something wrong or out of date on this page? Report it.